Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236100 | 0.75 | ALDH1A1 (0.51) | GSK3AGSK3BMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4237910 | 0.75 | NR1I2 (0.40) | GSK3AGSK3BMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4233139 | 0.73 | ALDH1A1 (0.36) | GSK3AGSK3BMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14086979 | 0.73 | MAPT (0.42) | MAPTALDH1A1SMN1; SMN2MEN1HTT | |
| SCHEMBL4231928 | 0.72 | ALDH1A1 (0.46) | GSK3AGSK3BMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4227995 | 0.71 | ALDH1A1 (0.38) | GSK3AGSK3BMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4231751 | 0.71 | MAPT (0.41) | GSK3AGSK3BMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14622097 | 0.71 | MAPT (0.36) | GSK3AGSK3BMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4237391 | 0.71 | BCHE (0.41) | GSK3AGSK3BALDH1A1MEN1HTT | |
| SCHEMBL4227297 | 0.70 | CA1 (0.41) | GSK3AGSK3BMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| EP-1896465-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | Takeda Cambridge Limited (GB) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007000582-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | GNRHR, GHRHR, FSHR | GSK3A 4636/4885GSK3B 4368/4885MAPT 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.